GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes- State-of-the-Art
We do think these drugs are very powerful and can be useful
No reconstitution errors
Given this unifying pathophysiology, GLP-1 RAs, with their powerful ability to act both centrally (controlling appetite and cravings) and peripherally (correcting systemic metabolic dysfunction, resolving hepatic steatosis and inflammation), to exert direct anti-carcinogenic effects, represent a truly multi-functional therapeutic tool
The dosing framework on this page is based on the published Phase 2 trial (Jastreboff et al., 2023, NEJM ) and the Rosenstock et al
Here we report crystal structures of the human GLP-1R transmembrane domain in complex with two different negative allosteric modulators, PF-06372222 and NNC0640, at 2.7 and 3.0 resolution, respectively